메뉴 건너뛰기




Volumn 24, Issue 1, 2014, Pages 168-187

Adaptive designs for confirmatory clinical trials with subgroup selection

Author keywords

Adaptive signature design; Stratified medicine; Subgroup analysis; Targeted therapy

Indexed keywords

PANITUMUMAB;

EID: 84891804052     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2013.857238     Document Type: Article
Times cited : (60)

References (44)
  • 1
    • 42649145667 scopus 로고    scopus 로고
    • Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • Amado, R., et al. (2008). Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 26:1626-1634.
    • (2008) Journal of Clinical Oncology , vol.26 , pp. 1626-1634
    • Amado, R.1
  • 3
    • 78249260148 scopus 로고    scopus 로고
    • Aspects of modernizing drug development using scenario planning and evaluation
    • Benda, N., Branson, M., Maurer, W., Friede, T. (2010). Aspects of modernizing drug development using scenario planning and evaluation. Drug Information Journal 44:299-315.
    • (2010) Drug Information Journal , vol.44 , pp. 299-315
    • Benda, N.1    Branson, M.2    Maurer, W.3    Friede, T.4
  • 4
    • 54349104178 scopus 로고    scopus 로고
    • Unbiased estimation of selected treatment means in two-stage trials
    • Bowden, J., Glimm, E. (2008). Unbiased estimation of selected treatment means in two-stage trials. Biometrical Journal 50:515-527.
    • (2008) Biometrical Journal , vol.50 , pp. 515-527
    • Bowden, J.1    Glimm, E.2
  • 8
    • 84876448156 scopus 로고    scopus 로고
    • Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection
    • Carreras, M., Brannath, W. (2012). Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection. Statistics in Medicine 32:1677-1690.
    • (2012) Statistics in Medicine , vol.32 , pp. 1677-1690
    • Carreras, M.1    Brannath, W.2
  • 9
    • 84858794156 scopus 로고    scopus 로고
    • Inflation in the number of eligibility criteria for industry-sponsored phase ii cancer clinical trial: Illustration over a 20-year period
    • Clisant, S., Clermont, A., Adenis, A., Penel, N. (2012). Inflation in the number of eligibility criteria for industry-sponsored phase ii cancer clinical trial: Illustration over a 20-year period. Contemporary Clinical Trials 33:459.
    • (2012) Contemporary Clinical Trials , vol.33 , pp. 459
    • Clisant, S.1    Clermont, A.2    Adenis, A.3    Penel, N.4
  • 12
    • 77954875817 scopus 로고    scopus 로고
    • Food and Drug Administration. Available at: (accessed January 1, 2013)
    • Food and Drug Administration. (2010). Guidance for Industry - Adaptive Design Clinical Trials for Drugs and Biologics. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM201790.pdf (accessed January 1, 2013).
    • (2010) Guidance for Industry - Adaptive Design Clinical Trials for Drugs and Biologics
  • 13
    • 27744537954 scopus 로고    scopus 로고
    • Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
    • Freidlin, B., Simon, R. (2005). Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11:7872-7828.
    • (2005) Clinical Cancer Research , vol.11 , pp. 7872-7828
    • Freidlin, B.1    Simon, R.2
  • 14
    • 65649112030 scopus 로고    scopus 로고
    • Exploring changes in treatment effects across design stages in adaptive trials
    • Friede, T., Henderson, R. (2009). Exploring changes in treatment effects across design stages in adaptive trials. Pharmaceutical Statistics 8:62-72.
    • (2009) Pharmaceutical Statistics , vol.8 , pp. 62-72
    • Friede, T.1    Henderson, R.2
  • 15
    • 78249260149 scopus 로고    scopus 로고
    • Refinement of the clinical scenario evaluation framework for assessment of competing development strategies with an application to multiple sclerosis
    • Friede, T., Nicholas, R., Stallard, N., Todd, S., Parsons, N., Valds-Mrquez, E., Chataway, J. (2010). Refinement of the clinical scenario evaluation framework for assessment of competing development strategies with an application to multiple sclerosis. Drug Information Journal 44:713-718.
    • (2010) Drug Information Journal , vol.44 , pp. 713-718
    • Friede, T.1    Nicholas, R.2    Stallard, N.3    Todd, S.4    Parsons, N.5    Valds-Mrquez, E.6    Chataway, J.7
  • 16
    • 84870869525 scopus 로고    scopus 로고
    • A conditional error function approach for subgroup selection in adaptive clinical trials
    • Friede, T., Parsons, N., Stallard, N. (2012). A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine 31:4309-4320.
    • (2012) Statistics in Medicine , vol.31 , pp. 4309-4320
    • Friede, T.1    Parsons, N.2    Stallard, N.3
  • 17
    • 33750884934 scopus 로고    scopus 로고
    • Confidentiality and trial integrity issues for adaptive designs
    • Gallo, P. (2006a). Confidentiality and trial integrity issues for adaptive designs. Drug Information Journal 40:445-450.
    • (2006) Drug Information Journal , vol.40 , pp. 445-450
    • Gallo, P.1
  • 18
    • 33745175516 scopus 로고    scopus 로고
    • Operational challenges in adaptive design implementation
    • Gallo, P. (2006b). Operational challenges in adaptive design implementation. Pharmaceutical Statistics 5:119-124.
    • (2006) Pharmaceutical Statistics , vol.5 , pp. 119-124
    • Gallo, P.1
  • 20
    • 22544469981 scopus 로고    scopus 로고
    • Sungroup analyses in randomized clinical trials: Statistical and regulatory issues
    • Grouin, J. M., Coste, M., Lewis, J. (2005). Sungroup analyses in randomized clinical trials: Statistical and regulatory issues. Journal of Biopharmaceutical Statistics 15:869-882.
    • (2005) Journal of Biopharmaceutical Statistics , vol.15 , pp. 869-882
    • Grouin, J.M.1    Coste, M.2    Lewis, J.3
  • 21
    • 33645762226 scopus 로고
    • A sharper Bonferroni procedure for multiple tests of significance
    • Hochberg, Y. (1988). A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802.
    • (1988) Biometrika , vol.75 , pp. 800-802
    • Hochberg, Y.1
  • 22
    • 0033566769 scopus 로고    scopus 로고
    • Statistical principles for clinical trials: ICH harmonized tripartite guideline
    • ICH E9 Expert Working Group
    • ICH E9 Expert Working Group. (1999). Statistical principles for clinical trials: ICH harmonized tripartite guideline. Statistics in Medicine 18:1905-1942.
    • (1999) Statistics in Medicine , vol.18 , pp. 1905-1942
  • 23
    • 79956157675 scopus 로고    scopus 로고
    • An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints
    • Jenkins, M., Stone, A., Jennison, C. (2011). An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 10:347-356.
    • (2011) Pharmaceutical Statistics , vol.10 , pp. 347-356
    • Jenkins, M.1    Stone, A.2    Jennison, C.3
  • 25
    • 34447264769 scopus 로고    scopus 로고
    • Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect
    • Jiang, W., Freidlin, B., Simon, R. (2007). Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute 99:1036-1043.
    • (2007) Journal of the National Cancer Institute , vol.99 , pp. 1036-1043
    • Jiang, W.1    Freidlin, B.2    Simon, R.3
  • 26
    • 70449529019 scopus 로고
    • Discrete sequential boundaries for clinical trials
    • Lan, K. K. G., DeMets, D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika 70:659-663.
    • (1983) Biometrika , vol.70 , pp. 659-663
    • Lan, K.K.G.1    Demets, D.L.2
  • 27
    • 0032732411 scopus 로고    scopus 로고
    • Adaptive sample size calculations in group sequential trials
    • Lehmacher, W., Wassmer, G. (1999). Adaptive sample size calculations in group sequential trials. Biometrics 55:1286-1290.
    • (1999) Biometrics , vol.55 , pp. 1286-1290
    • Lehmacher, W.1    Wassmer, G.2
  • 28
    • 84879187854 scopus 로고    scopus 로고
    • Group sequential enrichment design incorporating subgroup selection
    • Magnusson, B. P., Turnbull, B. W. (2013). Group sequential enrichment design incorporating subgroup selection. Statistics in Medicine 32(16):2695-2714.
    • (2013) Statistics in Medicine , vol.32 , Issue.16 , pp. 2695-2714
    • Magnusson, B.P.1    Turnbull, B.W.2
  • 29
    • 84873817347 scopus 로고    scopus 로고
    • A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials
    • Millen, B. A., Dmitrienko, A., Truberg, S., Shen, L. (2012). A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials. Drug Information Journal 46(6):647-656.
    • (2012) Drug Information Journal , vol.46 , Issue.6 , pp. 647-656
    • Millen, B.A.1    Dmitrienko, A.2    Truberg, S.3    Shen, L.4
  • 30
    • 0034876356 scopus 로고    scopus 로고
    • Adaptive group sequential designs for clinical trials: Combining the advantage of adaptive and of classical group sequential approaches
    • Müller, H.-H., Schäfer, H. (2001). Adaptive group sequential designs for clinical trials: Combining the advantage of adaptive and of classical group sequential approaches. Biometrics 57:886-891.
    • (2001) Biometrics , vol.57 , pp. 886-891
    • Müller, H.-H.1    Schäfer, H.2
  • 32
    • 77953105174 scopus 로고    scopus 로고
    • New strategies for treatment of kras mutant metastatic colorectal cancer
    • Prenen, H., Tejpar, S., Cutsem, E. V. (2010). New strategies for treatment of kras mutant metastatic colorectal cancer. Clinical Cancer Research 16(11):2921-2926.
    • (2010) Clinical Cancer Research , vol.16 , Issue.11 , pp. 2921-2926
    • Prenen, H.1    Tejpar, S.2    Cutsem, E.V.3
  • 33
    • 33750893179 scopus 로고    scopus 로고
    • Implementing adaptive designs: Logistical and operational considerations
    • Quinlan, J. A., Krams, M. (2006). Implementing adaptive designs: logistical and operational considerations. Drug Information Journal 40:437-444.
    • (2006) Drug Information Journal , vol.40 , pp. 437-444
    • Quinlan, J.A.1    Krams, M.2
  • 34
    • 82255183905 scopus 로고    scopus 로고
    • Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment
    • Rosenblum, M., Van Der Laan, M. J. (2011). Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment. Biometrika 98:845-860.
    • (2011) Biometrika , vol.98 , pp. 845-860
    • Rosenblum, M.1    Van Der Laan, M.J.2
  • 35
    • 67649345185 scopus 로고
    • An improved Bonferroni procedure for multiple test of significance
    • Simes, R. J. (1986). An improved Bonferroni procedure for multiple test of significance. Biometrika 73:751-754.
    • (1986) Biometrika , vol.73 , pp. 751-754
    • Simes . R, J.1
  • 36
    • 34547529442 scopus 로고    scopus 로고
    • A method for testing a prespecified subgroup in clinical trials
    • Song, Y., Chi, Y. H. (2007). A method for testing a prespecified subgroup in clinical trials. Statistics in Medicine 26(19):3535-3549.
    • (2007) Statistics in Medicine , vol.26 , Issue.19 , pp. 3535-3549
    • Song, Y.1    Chi, Y.H.2
  • 37
    • 77957962442 scopus 로고    scopus 로고
    • Adjusted significance levels for subgroup analyses in clinical trials
    • Spiessens, B., Debois, M. (2010). Adjusted significance levels for subgroup analyses in clinical trials. Contemporary Clinical Trials 31:647-656.
    • (2010) Contemporary Clinical Trials , vol.31 , pp. 647-656
    • Spiessens, B.1    Debois, M.2
  • 39
    • 18444383925 scopus 로고    scopus 로고
    • Point estimates and confidence regions for sequential trials involving selection
    • Stallard, N., Todd, S. (2005). Point estimates and confidence regions for sequential trials involving selection. Journal of Statistical Planning and Inference 135:402-419.
    • (2005) Journal of Statistical Planning and Inference , vol.135 , pp. 402-419
    • Stallard, N.1    Todd, S.2
  • 40
    • 84885768838 scopus 로고    scopus 로고
    • Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: Systematic review and meta-regression
    • Steinvorth, S., Röver, C., Schneider, S., Nicholas, R., Straube, S., Friede, T. (2013). Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: Systematic review and meta-regression. Multiple Sclerosis Journal 19:1580-1586.
    • (2013) Multiple Sclerosis Journal , vol.19 , pp. 1580-1586
    • Steinvorth, S.1    Röver, C.2    Schneider, S.3    Nicholas, R.4    Straube, S.5    Friede, T.6
  • 42
    • 66349125688 scopus 로고    scopus 로고
    • Adaptive patient enrichment designs in therapeutic trials
    • April
    • Wang, S.-J., Hung, H. M. J., O'Neill, R. T. (2009, April). Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 51:358-374.
    • (2009) Biometrical Journal , vol.51 , pp. 358-374
    • Wang, S.-J.1    Hung, H.M.J.2    O'neill, R.T.3
  • 43
    • 34648840242 scopus 로고    scopus 로고
    • Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
    • Wang, S.-J., O'Neill, R. T., Hung, H. M. J. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6:227-244.
    • (2007) Pharmaceutical Statistics , vol.6 , pp. 227-244
    • Wang, S.-J.1    O'neill, R.T.2    Hung, H.M.J.3
  • 44
    • 79957438038 scopus 로고    scopus 로고
    • Design and analysis considerations in clinical trials with a sensitive subpopulation
    • Zhao, Y. D., Dmitrienko, A., Tamura, R. (2010). Design and analysis considerations in clinical trials with a sensitive subpopulation. Statistics in Biopharmaceutical Research 2:72-83.
    • (2010) Statistics in Biopharmaceutical Research , vol.2 , pp. 72-83
    • Zhao, Y.D.1    Dmitrienko, A.2    Tamura, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.